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Nasal delivery of donepezil HCl-
loaded hydrogels for the treatment 
of Alzheimer’s disease
sitah Al Harthi  1,2,3, Seyed Ebrahim Alavi  3, Mahasen Ali Radwan4,  
Mona Mohamed El Khatib5,6 & Ibrahim Abdullah  Alsarra1
This study aims to prepare, characterize and evaluate the pharmacokinetics of liposomal donepezil 
HCl (LDH) dispersed into thiolated chitosan hydrogel (TCH) in rabbits. Various hydrogels including 
TCH were prepared, and after characterization, TCH was selected for subsequent evaluations, due to 
the promising results. TCH was then incorporated with LDH prepared by reverse phase evaporation 
method. The hydrogel was characterized using scanning electron microscope, dialysis membrane 
technique, and ultra-performance liquid chromatography methods. The optimized resultant was 
then evaluated in terms of pharmacokinetics in an in vivo environment. The mean size of LDH and 
drug entrapment efficiency were 438.7 ± 28.3 nm and 62.5% ± 0.6, respectively. The controlled drug 
release pattern results showed that the half-life of the loaded drug was approximately 3.5 h. Liposomal 
hydrogel and free liposomes were more stable at 4 °C compared to those in 20 °C. The pharmacokinetics 
study in the rabbit showed that the optimized hydrogel increased the mean peak drug concentration 
and area under the curve by 46% and 39%, respectively, through nasal route compared to the oral 
tablets of DH. Moreover, intranasal delivery of DH through liposomal hydrogel increased the mean 
brain content of the drug by 107% compared to the oral DH tablets. The results suggested that 
liposomes dispersed into TCH is a promising device for the nasal delivery of DH and can be considered 
for the treatment of Alzheimer’s disease.
Alzheimer’s disease (AD) is a dysfunction of central nervous system (CNS) and causes dementia, in which 
patients lose their memory1. AD results in neuronal deterioration, given rise to memory and cognitive impair-
ment as well as disturbance in daily activities. As a result, the patients thinking ability is disrupted, leading to 
psychiatric disorder1. In the last stages of the disease, patients require 24-h care2. Today, cholinergic hypothesis 
constitutes the basis for the development of most common therapeutics for AD treatment. According to this 
hypothesis, reducing the production of acetylcholine, as a neurotransmitter, leads to AD. Therefore, cholinester-
ase inhibitors (ChEIs) can be considered as potential targets for the treatment of AD3. Donepezil HCl (DH) is one 
of the ChEIs developed for AD treatment4.
DH, as a specific and reversible ChEI, increases the acetylcholine concentration in the cholinergic synapses4. 
Despite its therapeutic effects, it has various side effects, such as nausea and diarrhea, after oral administration5. 
Also, drug delivery to AD is limited, due to the blood brain barrier (BBB), restricting the brain penetration of 98 
and 100% of small and large molecule drugs, respectively6. To overcome these issues, hydrogel-based drug deliv-
ery systems and drug delivery through nasal route seem to be appropriate.
Nasal mucosa is characterized by high vascularization, large absorptive surface area, and the rapid onset of 
action4. Moreover, this route is an alternative, non-invasive, and painless technique for circumventing the BBB 
and delivering therapeutics to CNS4.
Also, hydrogels are cross-linked 3-dimensional (3D) networks, biocompatible with biological systems, and able 
to absorb the high content of water7. Most hydrogels are bio- and muco-adhesive8 and improve drugs bioavailability 
1Department of Pharmaceutical Science, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 
2Department of Pharmaceutical Science, College of Pharmacy, Shaqra University, Riyadh, Saudi Arabia. 3School 
of Pharmacy, The University of Queensland, Woolloongabba, 4102, Australia. 4Department of Pharmaceutics and 
Pharmaceutical Technology, College of Pharmacy, Egyptian Russian University, Bader City, Egypt. 5Department of 
Pharmaceutics, Faculty of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 6Department of Pharmaceutics, 
Faculty of Pharmacy, Cairo University, Cairo, Egypt. Correspondence and requests for materials should be addressed 
to M.M.E.K. (email: mona.elkhatib@pharma.cu.edu.eg) or I.A.A. (email: ialsarra@ksu.edu.sa)
Received: 20 December 2018
Accepted: 17 June 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:9563  | https://doi.org/10.1038/s41598-019-46032-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
more than conventional oral drug delivery systems through increasing the contact time between the drug and 
absorption site9. Therefore, hydrogels appear promising for brain drug delivery through nasal route10.
In this study, various hydrogels formulations were designed, and after characterization, thiolated chitosan 
hydrogel (TCH) was selected for incorporation with liposomal DH (LDH) for the intranasal delivery of DH as 
an anti-Alzheimer drug in rabbits. In this regard, various pharmacokinetic parameters, including the mean peak 
drug concentration (Cmax), time to reach Cmax (Tmax), and area under the curve (AUC) of the drug were evaluated. 
LDH incorporated into TCH could considerably contribute to the development of efficacious system for DH 
brain delivery, due to its promising properties. This formulation is a novel approach, reported for the first time 
for the brain delivery of DH which might result in the development of an innovative therapy for AD treatment.
Results and Discussion
Characterization of hydrogels. Drug loading efficiency. Drug loading efficiency is critical for polymer 
carriers as low drug loading increases the drug cost, decreases therapeutic efficacy, and causes inappropriate 
release profiles, leading to the limited efficiency of drug delivery systems11. Therefore, improving the drug load-
ing efficiency is important to obtain the efficient drug action. In the present study, the results showed high drug 
loading efficiency, confirming the potency of the method used for synthesizing DH-loaded hydrogels, in which 
drug entrapment efficiency for the hydrogels ranged from 79 to 95%.
Gel fraction. Gel fraction is the weight ratio of dry gel before and after swelling12. It indicates the covalent 
crosslinking of polymer chains13 and is inversely associated with the toughness of a polymeric network14. The 
poor mechanical properties of PVP limits its use for biomedical application, and its mixing with other polymers 
enhances its mechanical characteristics and usage as biomedical materials15.
In the present study, preparing the PVP hydrogels in aqueous polymer solution and cross-linking them using 
gamma ray was found as a simple and effective procedure. Gel fraction data presented in Table 1 (Supplementary 
Information) and Fig. 1 indicated that gel fraction was generally decreased with increasing PEG concentration 
and decreasing radiation dose. This results from the fact that PEG functions not only as a plasticizer, but also it 
decreases the cross-linking degree and maintains the gelation process between PVP chains, resulting in decreas-
ing the PVP cross-linking and further avoiding their physical interactions16. As PEG is an alcohol, it can function 
as a radical scavenger, and as a result, it can be used as an enhancer or a reducer of the hydrogel gelation based on 
the radiation dose. This effect can be reversed by increasing the radiation dose, which causes further cross-linking 
network chains and increasing the gel content17. Based on these facts, the difference between gel fraction values 
of the hydrogels prepared from only PVP (3, 4 and 6%) and hydrogels containing PEG 3% were statistically sig-
nificant (P < 0.05). These results were in agreement with the results of El-Mohdy et al.17 and Kim et al.18 studies; 
however, in the present study, chitosan and TCH showed comparable gel fraction values (65 and 62% for chitosan 
and TCH, respectively). The degree of polymer cross-linking is inversely proportional with the degree of swell-
ing19, and as the gel fraction increases, the lower swelling degree is achieved20.
Degree of swelling. It has been found that cross-linking density is inversely associated with the swelling degree21. 
Also, the extensibility and the elastic modulus are decreased as the swelling degree increases22. Moreover, a direct 
relationship between PEG content and the swelling degree of hydrogels has been reported as PEG blocks are 
hydrophilic and drive swelling23.
Figure 1. Effect of radiation dose on the hydrogel fraction in different formulations: (A) PVP 3% gels, (B) PVP 
4% gels and (C) PVP 6% gels.
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The results of swelling degree in the present study shown in Table 2 (Supplementary Information) and Fig. 2 
indicated that the swelling was generally increased by increasing PEG concentration and decreasing radiation 
dose. In other words, the amounts of swelling degree were inversely proportional with cross-linking density. 
Although these rules were not definite in the present study, the prepared hydrogels were generally followed these 
principles which were consistent with the results of previous studies15,23. Also, the swelling degree in thiolated 
chitosan (19.8%) was less than chitosan (21%) hydrogels, indicating that TCH had higher extensibility and elastic 
modulus than chitosan hydrogel.
The most common technique used for prolonging the residence time of topical drugs at the application site 
is to enhance formulations viscosity using polymers. Therefore, in a polymeric network, rigidity and elasticity 
depend upon rheological properties24.
Evaluation of the hydrogels rheological properties. Rheological measurements afford a quantitative character-
ization of the visco-elastic characteristics of a substance under the defined conditions25. These measurements 
provide valuable information about the behavior and probable behavior of various products, in terms of their 
viscosity and elasticity26. Flow behavior is an indirect measurement of product consistency and quality and is 
associated with several parameters, such as molecular weight and its distribution.
In the current study, the results of rheological measurements indicated an inverse relationship between vis-
cosity and shear rate, indicating shear thinning behavior of the samples (Figs 3 and 4). However, in the hydrogel 
prepared from PVP 6% and PEG 2%, there was an inverse phenomenon, in which the viscosity was increased by 
increasing the shear rate over time, known as rheopexy, as shown in Table 3 (Supplementary Information) and 
Fig. 3. Decreasing the viscosity of formulations under shear stress in a time-dependent manner is known as thix-
otropy. Also, the results showed that the shear thinning behavior was more obvious in those hydrogels prepared 
from PVP 4% compared to those prepared from PVP 6%. Moreover, TCH compared to chitosan showed less 
viscosity, and it was observed that TCH elasticity had a correlation with the polymer-linked thiol groups as shown 
in Table 3 (Supplementary Information) and Figs 3 and 427. Therefore, TCH derivatives could be considered as 
appropriate excipients for the preparation of liquid and semiliquid formulations, which could be stable on the site 
of drug application, such as mucous membranes24.
Mucoadhesion measurement of hydrogels. Contact time has a key role in bioadhesion as a sufficient contact time 
provides adequate hydration and swelling of the polymer and enhances the interpenetration of moisture and 
the formation of non-covalent interaction, resulting in the promotion of mucoadhesion28. Among the different 
instrumental variables influencing the mucoadhesive properties of polymers, contact force and time, and the 
removal speed of the probe from the mucosal tissue are the most efficient factors. Chain flexibility is the most 
important physical mechanism of mucoadhesion, where flexible polymer chains intend to interpenetrate between 
polymer chains and mucus to a suitable depth for developing a robust adhesive bond29. Also, diffusion theory 
explains the interpenetration of polymer and mucin (a glycoprotein in epithelial lining of respiratory tract) chains 
to an adequate depth to develop a semi-permanent adhesive bond. Adhesion force is enhanced with increasing 
the penetration degree of the polymeric chains25. This penetration rate is determined by the factors of diffusion 
coefficient, mobility, flexibility and the essence of the mucoadhesive chains and contact time7. According to the 
previous finding30, the interpenetration depth needed to develop an efficient bioadhesive bond was in the range 
of 0.2–0.5 μm.
Figure 2. Effect of different radiation dose on the swelling degree in different formulations: (A) PVP 3% gels, 
(B) PVP 4% gels and (C) PVP 6% gels.
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In the present study, Tables 4 and 5 (Supplementary Information) and Fig. 5 illustrate the impact of contact 
time on the detachment force. It was found that the detachment force was increased with increasing the contact 
time. This was in consistent with the results obtained by Wong et al.31. The results, also, showed that TCH and 
the hydrogel prepared from PVP 6% and PEG 2% had the highest and lowest mucoadhesive intensity, respec-
tively. Although the hydrogel prepared from PVP 4% and PEG 2% showed the highest force of mucoadhesion 
among PVP hydrogels, it had poor flexibility, while PVP 4% and PEG 3% hydrogel had less mucoadhesive 
properties but with better flexibility (Tables 4 and 5 (Supplementary Information), Fig. 5). Furthermore, it 
was found that, in all formulations, detachment force was decreased by increasing PVP concentration, while 
the force was increased with increasing PEG concentration. This finding was related to the PVP concentration 
as increasing PVP concentration causes the hydrogels to become more rigid, while PEG increases the elas-
ticity and the detachment force. Cationic polymers, such as chitosan, have a good bioadhesive property and 
swelling in contact with nasal mucosa32. TCH constitutes disulfide bonds with mucus glycoproteins through 
reduced thiol groups, which are available on the chitosan backbone. The presence of disulfide bonds inter- and 
intra- molecularly makes chitosan as a highly stable drug carrier30. The formation of disulphide bonds between 
TCH and cysteine rich sub domains of mucus glycoproteins will augment the mucoadhesiveness properties 
of TCH33. The chitosan cross-linking depends upon the accessibility of the cationic sites and the negatively 
charged species34.
Figure 3. Flow properties of the various hydrogels.
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In vitro and ex-vivo drug release from hydrogels. Drug delivery systems with controlled release 
properties are a new approach for the treatment of different diseases. In these systems, interactions between the 
drug, polymers and the used medium are the key factors which determine the release rate magnitude and release 
order35. The ability of a drug delivery system to extend the drug release in a controlled manner is defined as con-
trolled release. In this regard, brain diseases are specially good candidate for controlled release methods, due to 
the presence of BBB36.
Figure 6 and Table 1 show DH release from different hydrogels formulations. The formulation contains PVP 
4% and PEG 3% hydrogel showed the highest release rate (98.25%) of the drug among PVP hydrogels. These 
hydrogels were prepared by cross-linking at the radiation dose of 20 KGy as the efficient dose. It was identified 
that increasing the PVP content results in a decrease in the drug release rate, owning to the enhancement of the 
cross-linking density. In addition, with the increase of PVP concentration, the network formation is enhanced, 
and the elasticity and flexibility are decreased (Fig. 6). In contrast, PEG incorporation into hydrogels reduces the 
cross-linking density, network formation, and consequently increases the elasticity and flexibility, resulting in 
the enhanced release rate of drug. PEG is a hygroscopic molecule and absorbs water molecules from the release 
Figure 4. Flow curves of the various hydrogels.
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medium, leading to increasing the dissolving medium for the drug, reducing the hydrogel viscosity and increas-
ing the drug release. By increasing the polymer concentration, the viscosity of hydrogel also increases, resulting 
in reducing the drug release. Ko et al.37 study showed the relationship between the profile of drug release and 
viscosity of chitosan solution. Also, the current study showed that TCH had higher drug release rate compared 
to chitosan and hydrogels prepared from PVP 3% and PEG 3%. This is due to the fact that chitosan functions as 
permeation enhancer, and this effect intensifies in the presence of thiol groups38. Moreover, chitosan can increase 
the paracellular absorption route, which has a key role in the transmission of hydrophilic therapeutics across the 
membrane32. Table 1 demonstrates the accumulative release profiles of DH from hydrogels. The formulations 
(PVP 6%, PVP 6% and PEG 3% hydrogels) seem to be fit with Korsmeyer-Peppas mathematical model (r > 0.999). 
These findings were in agreements with previous studies’ results39,40. In conclusion, these findings indicated that 
the prepared hydrogels had the controlled drug release pattern, making them suitable for biomedical applications.
Figure 5. Effects of contact time on the adhesion force of different formulations: (A) PVP 3% gels; (B) PVP 4% 
gels; (C) PVP 6% gels; and (D) chitosan and thiolated chitosan gels.
Figure 6. DH release profile from different formulations: (A) PVP 3% gels; (B) PVP 4% gels; (C) PVP 6% gels; and 
(D) chitosan, thiolated chitosan, thiolated chitosan ex vivo, PVP 4% + PEG 3%, and PVP 4% + PEG 3% ex vivo.
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Histopathological effects of the hydrogels. Drug delivery systems must be safe for human clinical 
use41. In this regard, histopathological studies are commonly used for the toxicity assessment of formulations. 
Olfactory mucosa in sheep similar to other mammalians, such as human, constitutes of the olfactory epithelium 
and basal lamina propria. The olfactory epithelium by itself constitutes of basal, receptor and supporting cells, 
while Bowman’s glands in lamina propria are limited to the superficial part of the propria42.
The findings of the present study showed that PVP hydrogels without additives led to a slight histological 
change in the olfactory mucosa (Fig. 7). There was hypotrophy in the Bowman’s gland and cellular infiltration in 
the connective tissue lamina propria surrounding the gland compared to the control group, normal respiratory 
epithelium with preserved cilia. The olfactory epithelium appeared to be not affected. Hydrogel containing PVP 
4% and PEG 3% led to substantial histological changes in the mucosa of the olfactory epithelium, in which degen-
eration and sloughing of the epithelium surface were observed with ulcers in some regions of the epithelium. 
Degeneration and cellular infiltrations in the Bowman’s gland, dilation and congestion of the blood vessels were 
also observed. Other changes were apoptotic nuclei in the connective tissue lamina propria and Bowman’s gland. 
In the case of chitosan hydrogel (Fig. 7C), a marked cellular infiltration in the connective tissue lamina propria, 
apoptosis, and sloughing of the epithelium surface were observed associated with stratification of the epithelium 
(hyperplasia) in some regions. However, TCH (Fig. 7B) did not cause significant histological changes, in which 
the olfactory mucosa seemed to be similar to that of the control group with minor histological alterations. In 
this case, few degenerative changes in the epithelium surface and in the Bowman’s gland in some regions of the 
olfactory mucosa were observed. The ability of mucoadhesive polymers to interact with the mucus layer makes 
them suitable for incorporating with liposomes to inhibit the liposome clearance and increase the absorption of 
drugs loaded into liposomes43.
Characterization of liposomes. Liposome is a small vesicle with the composition identical to the cell 
membrane44. Reverse-rotary evaporation, as a simple operation, is used for producing high envelopment mon-
olayer liposome45.
In the present investigation, liposomes were prepared by two methods, and both were based on the reverse 
phase evaporation technique. In the first method, a short time sonication was used to prepare a water/oil emul-
sion from a two-phase system containing phospholipids in chloroform and phosphate buffer saline (PBS) con-
taining DH. The liposomes were formed by removing the residual solvent using continuous rotary evaporation 
under reduced pressure, while in the second method, the hydrogel was subjected to the strong vortex to convert 
the hydrogel into suspension. The liposomal size influences the drug encapsulation efficiency in liposomes46. The 
results of various studies showed that using reverse phase evaporation technique led to vesicles with the mean 
diameter of 200–500 nm47,48. The vesicles size prepared by this method relies on the lipid composition and solvent. 
In this study, the size of the prepared liposomes was 438.7 ± 28.3 nm. Also, the results of SEM imaging (Fig. 8) 
showed that the LDH particles were prepared as large unilamellar vesicles with both oval and spherical shapes. 
In addition, the drug entrapment efficiency of prepared liposomes using the first and second methods was found 
to be 38% ± 0.7 and 62.5% ± 0.64, respectively. The second method is widely used to prepare liposomes since this 
method helps to increase drug encapsulation efficiency to 77–79%49.
In vitro drug release from LDH incorporated into TCH. DH is freely soluble in water and can pro-
duce effective complexation, due to the desired ionization power50. The factors of hydrogel composition (type of 
polymer, drug and additives), geometry (size and shape)51, preparation method (in-situ drug loading and post 
loading methods)52, and environmental conditions during drug release determine the mechanism of release51. 
Gel type
Zero-order83 
Qt = Q0 + K0t
Higuchi model83 
Ft = Q = KH × t1/2
First-order83  




W01/3 − Wt1/3 = kt
K r2 K r2 K r2 N K r2 K r2
PVP 3% 0.036 0.9830 0.550 0.9323 0.00 0.9811 0.92 0.006 0.9853 0.000 0.9817
PVP 3% + PEG 1% 0.30 0.9642 0.444 0.8763 0.000 0.9603 0.91 0.008 0.9960 0.00 0.9616
PVP 3% + PEG 2% 0.133 0.9836 5.828 0.9571 0.002 0.9674 0.90 0.056 0.9973 0.001 0.9729
PVP 3% + PEG 3% 0.158 0.9903 2.422 0.9271 0.002 0.9735 0.9 0.094 0.9970 0.001 0.9795
PVP 4% 0.021 0.8990 0.302 0.7858 0.000 0.8948 0.97 0.001 0.9952 0.00 0.8962
PVP 4% + PEG 1% 0.046 0.8052 0.663 0.6894 0.000 0.7938 0.99 0.000 0.9878 0.000 0.8962
PVP 4% + PEG 2% 0.122 0.9646 1.831 0.8739 0.001 0.9444 0.98 0.025 0.9979 0.000 0.9511
PVP 4% + PEG 3% 0.246 0.9883 3.729 0.9144 0.004 0.9508 0.97 0.115 0.9956 0.001 0.9636
PVP 6% 0.011 0.9867 0.171 0.9110 0.000 0.9857 0.96 0.002 0.9994 0.000 0.9861
PVP 6% + PEG 1% 0.009 0.8357 0.142 0.8523 0.000 0.8468 0.92 0.007 0.8605 0.000 0.8464
PVP 6% + PEG 2% 0.021 0.9735 0.314 0.8891 0.000 0.9713 0.95 0.003 0.9976 0.000 0.9717
PVP 6% + PEG 3% 0.028 0.9839 0.427 0.9041 0.000 0.9812 0.96 0.002 0.9993 0.001 0.9821
Chitosan 0.102 0.9445 1.519 0.8482 0.001 0.9263 0.92 0.007 0.9926 0.000 0.9323
Thiolated chitosan 0.323 0.9923 4.943 0.9265 0.010 0.9320 0.95 0.132 0.9991 0.002 0.9498
Table 1. Release rate constants and correlation coefficients (r) obtained after fitting various mathematical 
models into the release profile of DH from hydrogels formulations.
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Figure 7. Histopathological photomicrograph of (A) the normal sheep nasal mucosa (control) (magnification 
size × 20); (B) nasal mucosa after treatment with hydrogels without additives. Hypotrophy in the Bowman’s 
gland and cellular infiltration in the connective tissue lamina propria surrounding the gland are perceivable; 
(C) nasal mucosa after treatment with the PVP + PEG hydrogels; (D) histological characterization of nasal 
mucosa after using chitosan hydrogel; and (E) nasal mucosa after treatment with thiolated chitosan hydrogel 
(magnification size × 10).
Figure 8. (A) SEM image of liposomes prepared by first reversible evaporator phase method; (B) SEM image of 
liposomes prepared by second reversible phase method.
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Drug loading method and physicochemical properties of the lipid membrane are the most important factors, 
influencing drug release rate from liposomes53.
In the current study, the drug release from LDH incorporated into TCH was less than LDH as positive control 
(Fig. 9). The higher release rate of DH from liposomes compared to liposomes incorporated into TCH might 
attribute to the retarded release from hydrogel54. As Fig. 9 shows, drug release from liposomes incorporated into 
TCH was higher (94.7%) than the most hydrogels, which might be resulted from the polymer linkage. This sug-
gested some defects occurred in the bilayer liposomes, due to applied forces on the phospholipid head-groups by 
intermolecular crosslinking55. Therefore, interactions between thiolated polymer matrix and LDH do not affect 
the controlled and sustained release profile55. The release profile of DH from liposome incorporated into TCH 
revealed best fit with Korsmeyer-Peppas model (Table 2)56.
Stability study. Stability is one of the important factors in the design and development of formulations. 
The assessment of size distribution is important to study the physical or colloidal stability of a formula-
tion under storage conditions and in a biological medium57. The physical stability of liposomes could be 
Figure 9. The profile of DH release from various liposomal hydrogels.
Mathematical models Zero-order F = K0*t
Higuchi model 
F = KH*t ʌ0.5
First-order  
F = 100* [1− Exp (−K1* t)]
Korsmeyer-Peppas 
F = kKP *tʌn
Hixson-Crowell 
F = 100*[1 − (1 − kHC*t)ʌ3]
Hydrogel type K r K r K r K r K r
Thiolated chitosan 0.322 0.9917 4.931 0.9259 0.008 0.9306 0.152 0.9917 0.9998 0.9988
Table 2. Release rate constants (K) and correlation coefficients (r) obtained after fitting various mathematical 
models into the release profile of LDH incorporated into TCH.
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studied by measuring the size of liposomes which is increased, owing to their aggregation and or fusion. The 
physical stability of liposomes can be increased by enhancing the amount of liposomes charge (positive or 
negative)58. Also, it has been found that the surface charge density of liposomes influences their distribution 
in an in vivo environment59. Drug release from liposome and change in liposome size could occur, due to 
those physical processes affecting the shelf life of liposomes, such as aggregation/flocculation and fusion/
coalescence. Often a colloidal dispersion is thermodynamically unstable60. Liposomal formulations which 
are physically stable preserve size distribution and drug entrapment efficiency. Such stability is determined 
by different factors, such as thermodynamics and colloidal properties of the system54. The size of particles 
for nasal delivery should be above 10 µm because the smaller particles (<10 µm) can be transferred to the 
tracheobronchial with the airstream, while larger particles will mostly deposit in the nose. Therefore, the 
size range of 40–60 µm is appropriate for nasal delivery61. The size of particles prepared in the present study 
ranged from 45–58 µm.
The storage results of the current study for various formulations were indicated in Figs 10–13. It was found 
that the morphology of liposome was affected by the temperature, where it was changed remarkably at 20 °C, 
while it was approximately stable at 4 °C. It was perceived that liposomes incorporated into TCH were considera-
bly more stable than the unincorporated ones (Fig. 13).
Chromatographic system and conditions. In the present study, the blank plasma (Fig. 14A) in compar-
ison to the spiked plasma samples did not show significant interfering endogenous peaks at the retention times 
corresponded to DH (Fig. 14B1,C1) and IS (Fig. 14B2,C2), indicating the specificity of the assay. The chromato-
graphic behavior of QC samples was similar to that of actual plasma samples (Fig. 14B1 vs. B2,C1 vs. C2).
The chromatograms resulted from plasma sample containing DH and IS collected 12 h after nasal administra-
tion of LDH incorporated into TCH to the rabbits are shown in Fig. 14C. The peaks corresponded to DH and IS 
were distinct with the retention times of approximately 1 min and 2.6 min, respectively. The chromatographic run 
time of 3.5 min was sufficient for sample analysis.
To evaluate the linearity of the method, calibration curves were constructed using the six series of plasma sam-
ples containing 1–50 ng/mL of DH. The linear relationship (Y = 0.013 + 0.251X) was obtained between the peak 
area ratio of DH to that of IS versus the corresponding concentration of DH (with correlation coefficient (r) of 
>0.992 for all tested standard calibration curves). The validation of the calibration curve linearity was confirmed 
using high value of the correlation coefficient. The precision values for intra- and inter-day were <16.5% and the 
accuracy was <17.6 for DH concentrations62.
Figure 10. SEM images of LDH incorporated into TCH during stability study, (A1) liposomes stored at 4 °C 
for one week; (A2) liposomes stored at 4 °C for 2 weeks; (A3) liposomes stored at 4 °C for 3 weeks; and (A4) 
liposomes stored at 4 °C for 4 weeks.
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Pharmacokinetic study. After validating of the proposed bio-analytical method, it was successfully used to 
measure the plasma DH concentration for pharmacokinetic study in the New Zealand white rabbits. Aside from 
the economic reasons, rabbits are common laboratory animals because of their size, temperature and ability to 
produce genetically homogeneous strains63. In the current study, New Zealand white rabbits, as a well-controlled 
animal model, were used to evaluate the absorption potency of formulations from nasal route64.
Time profiles of DH plasma concentration (mean ± SD) in the rabbits after oral administrations of 5 mg of DH 
tablet and 5 mg of nasal LDH incorporated into TCH were shown in Fig. 15. The pharmacokinetics parameters 
for the tablet and LDH incorporated into TCH after oral and intranasal administration of DH are summarized in 
Table 3. It was found that the maximum plasma concentration of DH was achieved 1 h after the intranasal admin-
istration of LDH incorporated into TCH and 1.7 h after oral tablets administration. Cmax was 12 ± 1.3 ng/mL and 
8.2 ± 1.4 ng/mL for intranasal administration of LDH incorporated into TCH and oral administration of DH 
tablets, respectively, indicating the potency of liposome incorporated into TCH to increase Cmax through nasal 
route by 46%. Moreover, intranasal formulation increased the AUC by 39% compared to the oral tablets of DH. 
Overall, the results of DH measurement in the blood and brain proved that the intranasal DH delivery through 
LDH incorporated into TCH caused higher DH concentration in the blood circulation and brain compared to 
the oral tablets of DH. The results showed that the mean brain content of DH was >2-fold through intranasal 
administration of LDH incorporated into TCH compared to the oral tablets. This confirmed that the intranasal 
LDH incorporated into TCH is superior for DH delivery to the rabbit brain compared to the oral tablets.
Conclusion
In the current study, the synthesis of different DH hydrogels was reported for intranasal DH delivery. They were 
synthesized using gamma radiation and different natural and synthetic polymers. After in vitro characterization, 
TCH was selected for incorporating with LDH and subsequent pharmacokinetic evaluation in rabbits. The for-
mulation was administered through nasal route. The in vivo results showed that LDH incorporated into TCH 
significantly increased the blood concentration and the brain content of DH compared to the oral tablets of DH. 
In conclusion, this study suggests further investigation of LDH incorporated into TCH in the animal model of 
Alzheimer disease.
Materials and Methods
Materials. DH was provided from Jai Radhe Sales (Gujarat, India). Chitosan (103.2 g/mol, degree of deacetyl-
ation 76.6%), 2-imino thiolane hydrochloride, 2-mercaptoethanol, triethanolamin reagent grade, formic acid 
(ultra-performance liquid chromatography MS/MS (UPLC MS/MS) grade), clopidogrel (as internal standard 
(IS)), ammonium formate, and acetonitrile were purchased from Sigma Aldrich Company (St. Luis, MO, USA). 
Cholesterol (CHOL) and dipalmitoylphosphocholine (DPPC) were purchased from Fisher Scientific Company 
(Fair Lawn, NJ, USA) and Avanti Polar Lipid Inc., (Birmingham, AL, USA), respectively. Polyvinyl pyrolidone 
(PVP), known as Luviskol® K-9, was purchased from BASF (Aktien gesellschaft Ludwig Shafen, Germany). 
Polyethylene glycol 600 (PEG600) was obtained from Merck Schuchardt (Hohenbrunn, Germany). Lactic acid 
glutaraldehyde 50% solution and chloroform were purchased from BDHL laboratory Supplies (PooleBH151TD, 
Figure 11. SEM images of LDH incorporated into TCH during stability study, (A1) liposomes stored at 20 °C 
for one week; (A2) liposomes stored at 20 °C for 2 weeks; (A3) liposomes stored at 20 °C for 3 weeks; and (A4) 
liposomes stored at 20 °C for 4 weeks.
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England). Mono basic potassium dihydrogen phosphate and cellophane membrane (Spectra/Por® Dialysis 
Tubing from regenerated cellulose) with cut-off 12–14000 Da were purchased from panreac Quimica, SA, 
(Barcelona, Espana) and Spectrum Laboratories (Houston, TX), respectively. All chemicals used were of analyti-
cal grade and were used as received.
In vitro study equipment. Drug diffusion from different formulations was evaluated using a vertical jack-
eted 15 mL Franz Cell with 12 mL receptor volume provided by PermeGear Inc. (3575 North Drive, Bethlehem, 
PA 18015, Ref n.: #6G-01-00-20-15). Rotavapor R-210 from Büchi Labortechnik AG, Flawil, Switzerland was used 
for liposome preparation. Morphology of the formulations was evaluated using scanning electron microscopy 
(SEM) (JSM-6060; JEOL, Tokyo, Japan). The mean particle size of the formulations was determined by dynamic 
light scattering (DLS) using 90 Plus particle size analyzer (Laser nanoparticle size analyzer model no. 90 Plus- 
software version 3.74, Brookhaven Instruments, Holtsville, New York, USA). Milli-Q-Plus system (Millipore sys-
tems®, France) was used for preparing de-ionized water.
Preparation of donepezil HCl-loaded PVP hydrogels. PVP hydrogel was synthesized based on the 
method described by Abd El-Mohdy et al.17 with some modifications. Briefly, PVP (3, 4, 6% w/w) with (1, 2, 
3% w/w) and without PEG were prepared in 100 mL of deionized water, and the samples were stirred (5 min, 
30 RPM). The solutions were transferred in glass bottles, and nitrogen was bubbled in the solutions to remove 
oxygen. Next, the bottles were sealed and irradiated at room temperature by gamma radiation produced from 
Cobalt-60 source with the doses of 15, 20, 25, 30 KGy. The products were fully sterile permanent hydrogels. The 
radiation time was measured according to the radiation source dosing rate (51.7 Gy/min). DH was also homoge-
neously dispersed in the hydrogels after crosslinking at the final drug concentration of 20 mg/g. The pH value of 
the prepared hydrogels was adjusted at 6.4 ± 0.15 by triethanolamin. The blank hydrogels were prepared without 
adding the drug.
Preparation of donepezil-loaded chitosan hydrogel. The chitosan hydrogel was prepared according 
to Chen et al.65 study. For this purpose, 2 g chitosan were added into acetic acid solution (100 mL, 0.1 M) and 
stirred (room temperature, 150 RPM) to achieve a homogeneous solution. Chitosan contains -NH2 amino group 
which can interact with glutaraldehyde as a cross-linking agent66. The cross-linking reaction between chitosan 
and glutaraldehyde was carried out at room temperature for 4 h. The pH value of hydrogel was adjusted to nasal 
(pH 5.5 ± 0.15). Also, the drug was loaded into hydrogel as mentioned before.
Preparation of donepezil HCl-loaded thiolated chitosan hydrogel. TCH was prepared according to 
the method described by Andreas et al.67 with some minor modifications. Briefly, a chitosan solution (1 g/700 mL 
Figure 12. SEM images of LDH during stability study, (B1) liposomes stored at 4 °C for one week; (B2) 
liposomes stored at 4 °C for 2 weeks; (B3) liposomes stored at 4 °C for 3 weeks; and (B4) liposomes stored at 4 °C 
for 4 weeks.
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of 1% acetic acid) was prepared, and 0.2 g of 2-iminothiolane HCl (Trauts reagent) was added. pH was adjusted to 
nasal (pH 5.5 ± 0.15). The oxidation process during the coupling reaction was inhibited using 2-mercaptoethanol 
at the final concentration of 3% (v/v). After 24-h incubation (room temperature, 200 RPM), the mixture was dia-
lyzed against 5 mM HCl, 5 mM HCl containing 1% NaCl twice, 5 mM HCl, and 1 mM HCl, respectively, and then 
stored at 4 °C. The drug was incorporated as before.
Characterization of hydrogels. Drug loading efficiency. Drug loading efficiency was indirectly meas-
ured; for this purpose, the swollen hydrogels incubated with DH were separately removed from the drug 
solutions, washed with 10 mL of distilled water, and were then dried in an oven at 37 °C for 24 h. The drug con-
centration remained in the solution was measured spectrophotometrically at 230 nm. The drug loading efficiency 






where Wdg is the mass of the drug loaded into hydrogel and Wg is the amount of initial drug.
Rabbit number Intranasal Tablet
Properties 1 2 3 4 Mean ± SD 1 2 3 Mean ± SD
Dose (mg) 0.4 0.4 0.4 0.4 0.4 ± 0.0 0.4 0.4 0.4 0.4 ± 0.0
AUC(0-t), (mg/l)h 15.1 33.4 16.3 12.3 19.3 ± 2.1 16.4 11.4 13.9 13.9 ± 2.5
Cmax, (ng/ml) 15.2 15.4 10.9 6.3 12.0 ± 1.3 7.4 6.4 10.9 8.2 ± 1.4
Tmax, (h) 1.0 1.0 1.0 1.0 1.0 ± 0.0 2.0 1.0 2.0 1.7 ± 0.2
T1/2, (h) 8.4 1.1 7.4 6.2 5.8 ± 0.7 8.4 9.5 5.3 7.7 ± 2.2
MRT, (h) 17.5 5.4 14.2 14.7 13.0 ± 1.4 15.9 20.7 12.6 16.4 ± 1.5
CI/F, (L/h)/kg 3.1 3 3.7 4.5 3.6 ± 0.4 3.2 3.1 4.6 3.6 ± 0.7
Brain content, (ng/g) 29.1 52.8 34.4 33.5 37.5 ± 3.5 4.7 16.6 33.1 18.1 ± 1.8
Table 3. Pharmacokinetics parameters for the tablet and intranasal LDH incorporated into TCH in rabbit 
plasma and brain content. *MRT: mean residence time.
Figure 13. SEM images of LDH during stability study, (B1) liposomes stored at 20 °C for one week; (B2) 
liposomes stored at 4 °C for 2 weeks; (B3) liposomes stored at 20 °C for 3 weeks; and (B4) liposomes stored at 
20 °C for 4 weeks.
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Gel fraction. The dried gels were immersed in hot water for 24 h, and water was changed every 4 h with fresh 
one. The gel fraction was determined by measuring the initial weight of dry gel before extraction and the weight 








where Wf and WO are the weight of dry gel before and after extraction, respectively.
Degree of swelling. The degree of swelling is defined as the water absorption capacity of hydrogel. The weighed 
dried hydrogels were immersed in redistilled water and incubated for 24 h (room temperature) to reach the equi-
librium state of swelling. The superficial water on the swollen gel was then removed using tissue paper, and imme-
diately weighed. The degree of swelling was calculated using formula (3):
=
−






where Ws is the weight of the swollen gel and Wd is the weight of dry gel68.
Evaluation of the hydrogels rheological properties. The rheograms of the bioadhesive hydrogels were obtained at 
37 °C using a rheometer equipped with a cone and plate measuring system. Samples were carefully put into the 
plate, in which formulation shearing did not occur and the parameters of shear rate, shear stress, and viscosity 
were monitored to investigate the flow profile, zero-rate viscosity, and thixotropy. The rheograms were obtained 
from at least three determinations69.
Mucoadhesion measurement of hydrogels. Mucoadhesion strength of the hydrogels was measured to 
evaluate their adhesion capability onto the mucus membrane. Nasal mucosal tissue was excised from the noses of 
Figure 14. (A) Chromatogram of blank plasma; (B) UPLC MS/MS chromatogram of extracted of spiked 
plasma with 1 ng DH and 40 ng IS; (C) UPLC MS/MS chromatogram of the extracted of DH 12 h after intranasal 
administration to rabbits and multiple reaction-monitoring (MRM) transitions of IS.
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freshly slaughtered sheep and stored on ice during transport to the laboratory. The nasal mucosa was immediately 
separated from the underlying cartilage (the time of tissue excision and mucosa separation should not be more 
than 30 min) by blunt stripping using a pair of tweezers70. An instron machine with a 5 K newton (N) load cell and 
1.2 cm diameter metallic cylindrical probe were used for the evaluation of mucoadhesion properties. Mucosa was 
attached to the lower and upper end of the instrument probe using cyanoacrylate glue, and 200 mg of hydrogel 
samples were then placed on the lower mucosa. Upper probe which hold the nasal mucosa was lowered onto the 
surface of the hydrogels until the contact was occurred with the initial force of 0.5 N. After a contact period of 
120 s, the upper probe was withdrawn and moved vertically upward to separate two surfaces with a constant speed 
of 5 mm s−1 until failure occurred between the surfaces. The mucoadhesion studies were performed at room tem-
perature and 50% relative humidity. The data were collected, and the calculations were carried out using Instron® 
Series IX automated material tester software, version 8.32.00. Each measurement was repeated at least 5 times70.
The effect of contact times of 30, 120, 300 and 600 s was evaluated on the mucoadhesion properties of the var-
ious hydrogels. The instron was adjusted with a probe speed of 5 mm s−1 and a contact force of 0.5 N. In addition, 
a sheep nasal mucosal membrane was used as a biological membrane70.
In vitro drug release form hydrogels. In vitro release studies were performed at 37 °C using the Franz 
diffusion cell. Briefly, 0.5 g of medicated formula containing 5 mg of DH was packed into each of three cell donor 
chambers, in which no air bubbles were produced between the formulation and donor surface of the cellophane 
membrane. The receptor phase was filled with PBS (pH 5.5) and continuously stirred (100 RPM) during the 
experiment to ensure homogeneity. The samples were taken at the different time intervals (0.5, 1, 1.5, 2, 2.5, 3, 
Source (ESI+) and analyzer Settings
Capillary voltage (kv) 1
Cone voltage (v) 35
Extractor (v) 1
Radio frequency lens (v) 0.2
Source temperature (C) 150
Desolvation temperature (C) 400
Cone gas flow (L/h) 50
Desolvation gas flow (L/h) 800
Collision energy (eV) 27
Collision gas flow (mL/min) 0.25
Table 4. Setting for mass spectra MS/MS detection of DH.
Figure 15. DH plasma concentration time profiles in rabbits after intranasal administration of LDH 
incorporated into TCH (n = 6) and oral administration of oral DH tablet (n = 6).
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3.5, 4, 4.5 and 5 h) and analyzed spectrophotometrically at the wavelength of 230 nm. The cumulative percentage 
of drug release was determined and plotted against time. All in vitro drug release studies were performed in 
triplicate70,71.
Ex-vivo drug release from hydrogels. Ex-vivo experiments were performed using excised sheep mucosal 
tissues. The nasal mucosa was prepared as mentioned at the section of mucoadhesion measurement. Samples 
were taken and inserted into the Franz diffusion chambers where the apical side of the tissue was typically faced 
with the donor compartment. Franz diffusion cells (final volume of 12 mL) were used to measure the DH release 
from the hydrogel formulations. For this purpose, 5 mg of the hydrogel containing 0.5 mg of DH was placed on 
the upper side of the nasal mucosa. The donor half-cell was then placed on the top of the receptor half-cell and 
clamped. The donor and the receiver compartments containing PBS (pH 5.5) were kept in the intimate contact 
and the temperature was maintained at 37 °C72.
Histopathological effects of hydrogels. The sheep’s nasal mucosa was prepared as mentioned before. 
The mucosal tissues were incubated in the various hydrogels for 5 h at 25 °C, and the tissues were fixed in 10% 
formalin solution for 48 h. Next, the tissues were embedded in paraffin wax. They were then sectioned (7 µm) and 
placed on glass slides. Later, they were stained with hematoxylin and eosin (H&E). The sections were evaluated 
using a light microscope connected to a digital camera to measure any changes. Mucosal tissues incubated in 
isotonic PBS (5 h) were considered as a control for comparison70.
Preparation of liposomes. Liposomes were synthesized using reverse phase evaporation technique. For 
this purpose, DPPC: CHOL (1.6:1 molar ratio) were dissolved in chloroform, and then the organic solvent was 
removed using rotary evaporator to form a thin film73. Next, 5 mg of DH was dissolved in PBS (pH 5.5), and the 
resultant was added into the thin film74.
Also, LDH was prepared by a method described by Turner et al.63. Briefly, 150 mg of DPPC and 50 mg of 
CHOL (1.6:1 molar ratio) were dissolved in chloroform in a round flask. Next, 5 mg of DH was dissolved in PBS 
and injected into lipid solution. The round flask was then capped with a glass stopper and sonicated for 5 min. 
Next, the solvent was evaporated using rotatory evaporator at 45 °C under vacuum condition, and then the result-
ant was vigorously vortexed for 5 min. The resultant was again evaporated to make sure the organic solvent was 
completely removed. The cycles of 10-min drying and 10-min vortexing were repeated thrice64.
Characterization of liposomes. The mean particle size and the morphology of the liposomes were deter-
mined using laser particle size analysis and SEM imaging, respectively75. Also, drug entrapment efficiency was 
evaluated using dialysis method. Briefly, the liposome suspension was transferred into a dialysis tube membrane 
(donor compartment). The dialysis bag was immersed into 200 mL of PBS (pH 5.5) and stirred (120 RPM, 4 h). 
Next, the drug concentration in receptor compartment was determined through the measurement of absorbance 
at 230 nm71,76. The drug entrapment efficiency (EE) was then calculated using formula (4).
=
−




Preparation of liposomal hydrogel. The incorporation of the liposomes into the TCH was achieved by 
slow mechanical mixing of liposome and hydrogel using a spatula77.
In vitro drug release from LDH incorporated into TCH. In vitro drug release study was performed 
using cellophane dialysis membrane (cut-off 12–14 kDa). The membrane was hydrated with PBS as the receptor 
medium (pH 5.5) for 12 h. Next, 0.5 g of the liposomal hydrogel containing 0.5 mg DH was suspended into 12 mL 
of PBS, transferred into dialysis bag as the donor medium, and stirred (37 °C, 120 RPM). Two milliliter aliquots 
were then taken at the fixed time intervals (0, 60, 120, 180, 240, 300, and 360 min) and were instantly replaced 
with an equal volume of the fresh buffer. All samples were analyzed for DH content by spectrophotometry at 
230 nm. The experiment was carried out in triplicate78.
Stability study. According to the obtained results, TCH provided the most promising results among differ-
ent hydrogels in terms of mucoadhesion properties and histopathological effects; therefore, from now on, we will 
consider only TCH in the subsequent experiments.
LDH and LDH incorporated into TCH were stored at 4 °C and 20 °C for 28 days. The mean size of particles in 
the formulations were examined using SEM at the different time intervals (7, 14, 21, and 28 days) to estimate the 
effect of different storage temperatures on physical stability of the liposomes74.
Chromatographic system and conditions. The analytical detection of DH was carried out using a 
Waters Tandem Quadrupole Mass Spectrometer (TQDTM), with cooling autosampler and column oven, equipped 
with electrospray ionization (ESI) interface. The ESI source was set in negative ionization mode as shown in 
Table 4. An ACQUITY UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) was used for the drug separation 
using mobile phase of 5 mM ammonium formate and 1% acetonitrile in water (pH 3) as solvent A and 0.1% 
formic acid in acetonitrile as solvent B with gradient elution at a flow rate of 0.4 mL/min. The gradient began 
with 80% eluent A and changed linearly to 20% A within 3.5 min at 40 °C. In addition, to control data acquisi-
tion, MassLynx V4.1 software with automated data processing using the QuanLynx software was utilized (Waters 
Corp., Milford, USA)79.
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Preparation of DH standards and quality control samples. Stock standard solutions of DH and IS 
from clopidogrel were synthesized in methanol (0.5 mg/mL) and stored in 4-mL amber glass vials at −20 °C. 
Also, various working standard solutions of DH (0.01–100 µg/mL) and 8 µg/mL of IS were prepared in methanol 
and freezed in amber vials at −20 °C. In addition, the solutions of plasma standard calibration were prepared in 
replicate (n = 6) at the drug concentrations of 1, 5, 10, 20, 50 ng/mL. Next, 40 µL of the DH working solutions and 
40 µL of the IS were diluted by 200 µL of blank rabbit plasma. Low, medium and high concentration of quality 
control (QC) samples at the drug concentrations of 1, 10, 50 ng/mL with 100 ng/mL of IS were prepared as well79.
Pharmacokinetics study. Seven New Zealand white rabbits with the mean weight of 3 ± 0.5 kg obtained 
from KSU Laboratory Animal Facility were used in this study as two groups (n = 3 and 4). All the methods and 
protocols of animal studies were in accordance with the relevant institutional guidelines and regulations and were 
approved and permitted by Animal Experimentation Ethics Committee, King Saud University (Riyadh, Saudi 
Arabia). The animals were housed and fasted for 12 h before the study and had free access to water during the 
experiment. A cannula was inserted into marginal ear vein for blood sampling and flushed with heparin-normal 
saline solution. The first group received LDH incorporated into TCH through nasal route and the second group 
received oral tablet of commercial DH. LDH incorporated into TCH formulation was administered by nasal 
dropper having a wide orifice inserted 5 g of liposomal hydrogels containing 5 mg of DH into nostrils of the rab-
bits while they were in supine position. The rabbit was kept in this position for 1 min after administration. A total 
dose of 5 mg of DH was given to rabbits and 5 mg oral tablet was dispersed in acacia and administered through 
oral route by dropper80.
One milliliter of blood samples collected from cannulated marginal vein before dose administration was con-
sidered as a reference level (time point zero) and at time intervals (1, 2, 4, 6 h) in heparinized vacuum glass tubes 
after administration. The cannula was flushed with heparin in normal saline solution after taking each sample. 
The plasma was separated by centrifugation method at 1000 RPM for 10 min and stored at −20 °C until the time 
of analysis80.
To precipitate the proteins of the collected plasma samples, 200 µL of aliquoted samples (or calibration stand-
ard or QC sample) and 40 µL of IS working solutions were transferred into 1.5-mL Eppendorf tubes, and the 
mixtures were vortexed for 10 s. Next, 1 mL of acetonitrile was added, and the mixture was vortexed for 1 min, 
followed by centrifugation at 20,000 RPM for 15 min at 4 °C. The supernatant was transferred into a 1.5-mL 
Eppendorf tube and evaporated under a gentle stream of nitrogen. The residue was reconstituted in 100 µL of 
mobile phase, vortexed for 1 min, centrifuged at 4000 RPM for 4 min, and transferred into a plastic autosampler 
vial with pre-slit septum (Waters, USA). Two microliters of the resultant were then injected into the UPLC MS/
MS system79.
To evaluate brain concentration of DH, the rabbits’ brain was removed, weighed and homogenized to liquefy 
the brain tissues. Next, 0.2 µg of the resultant was subjected to the determination of DH brain concentration using 
UPLC MS/MS system using the above-mentioned protocol81,82.
Data and statistical analysis. The in vitro results were shown as the mean ± standard deviation (SD) of 
triplicate (n = 3), while the in vivo results were expressed as mean ± SD of triplicate (for standard curve) and 
calculated by linear regression without weighing using formula 5:
= +Y a bX (5)
where Y is the ratio of area under peak (AUP) of the drug to the IS, a is intercept, b is slope, and X is the DH 
concentration.
The pharmacokinetics parameters were calculated using model-independent methods and the terminal elim-
ination rate constant (λn) was estimated using linear regression analysis of the terminal portion of the log-linear 
blood concentration–time profile of DH. Also, the terminal elimination half-life (t1/2) was calculated from the 






The Cmax and Tmax were obtained directly from the individual blood levels. The AUCs (µg mL−1 h) were meas-
ured by the linear trapezoidal rule and extrapolated to time infinity by the addition of C Last/λn, where C Last was 







The concentration difference at each day was examined using student t-test, and one-way analysis of variance 
(ANOVA) was applied to evaluate the reproducibility of the assay using IBM SPSS 20 Statistics. The level of con-
fidence was 95%79.
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